Adalimumab: Perbedaan antara revisi

Jelajahi riwayat secara interaktif

Konten dihapus Konten ditambahkan

VisualTeks wiki

Revisi per 21 Februari 2024 09.51 sunting WanaraLima (bicara \| kontrib) 1.718 suntingan Dibuat dengan menerjemahkan halaman "User:Mr. Ibrahem/Adalimumab" Tag: halaman dengan galat kutipan Terjemahan Konten Terjemahan Konten v2		Revisi terkini sejak 19 Oktober 2024 06.59 sunting balikkan Muhammad Anas Sidik (bicara \| kontrib) 24.726 suntingan Tidak ada ringkasan suntingan Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan
(4 revisi perantara oleh 2 pengguna tidak ditampilkan)
Baris 9: <!-- Pharmacokinetic data -->\|bioavailability=64% (subcutaneous), 0% ([[per os\|By mouth]])\|protein_bound=\|metabolism=\|elimination_half-life=10–20 days\|excretion=<!-- Chemical and physical data -->\|C=6428\|H=9912\|N=1694\|O=1987\|S=46\|chemical_formula=\|smiles=CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=C1C(=O)NCC(O)=O\|StdInChI=\|StdInChI_comment=\|StdInChIKey=\|molecular_weight=144190.3\|density=\|melting_point=\|melting_high=\|melting_notes=\|boiling_point=\|boiling_notes=\|solubility=\|specific_rotation=}} '''Adalimumab''' adalah obat yang digunakan untuk mengatasi kondisi seperti [[Rheumatoid Arthritis\|rheumatoid arthritis]],[[psoriasis]], [[penyakit Crohn]], psoriatic arthritis, uveitis, [[Ankilosing spodilitis\|ankilosing spondilitis]], [[kolitis ulseratif]], hidradenitis suppurativa, dan juvenile idiopatik arthritis . <ref name="AHFS2019">{{Cite web\|date=14 May 2018\|title=Adalimumab Monograph for Professionals\|url=https://www.drugs.com/monograph/adalimumab.html\|website=Drugs.com\|publisher=American Society of Health-System Pharmacists\|archive-url=https://web.archive.org/web/20201121141501/https://www.drugs.com/monograph/adalimumab.html\|archive-date=21 November 2020\|access-date=18 March 2019\|url-status=live}}</ref> <ref name="BNF76">{{Cite book\|date=2018\|title=British national formulary: BNF 76\|publisher=Pharmaceutical Press\|isbn=9780857113382\|edition=76\|pages=1074}}</ref> <ref name="hidradenitis suppurativa">{{Cite web\|date=11 September 2015\|title=FDA Clears Adalimumab (Humira) for Hidradenitis Suppurativa\|url=https://www.medscape.com/viewarticle/850897\|publisher=Medscape\|archive-url=https://web.archive.org/web/20210121031028/https://www.medscape.com/viewarticle/850897\|archive-date=21 January 2021\|access-date=13 October 2017\|url-status=live}}</ref> Penggunaan obat ini hanya direkomendasikan untuk orang yang belum mendapatkan respon baik dari pengobatan lain. <ref name="BNF76"~~>{{cite~~ ~~book\|title=British national formulary: BNF 76\|date=2018 \|publisher=Pharmaceutical Press\|isbn=9780857113382\|pages=1074\|edition=76}}<~~/~~ref~~> Rute pemberian obat Ini digunakan melalui [[penyuntikan subkutan]] . <ref name="AHFS2019"~~>{{cite~~ ~~web \|title=Adalimumab Monograph for Professionals \|url=https:~~//www.drugs.com/monograph/adalimumab.html \|website=Drugs.com \|publisher=American Society of Health-System Pharmacists \|date=14 May 2018 \|access-date=18 March 2019 \|archive-date=21 November 2020 \|archive-url=https://web.archive.org/web/20201121141501/https://www.drugs.com/monograph/adalimumab.html \|url-status=live }}</ref> Kejadian efek samping yang umum terjadi selama penggunaan obat ini seperti, rasa nyeri di daerah penyuntikan, ruam, dan, [[Infeksi saluran napas atas\|infeksi saluran pernapasan atas]]<nowiki/>sakit kepala. <ref name="AHFS2019"~~>{{Cite~~ ~~web\|date=14 May 2018\|title=Adalimumab Monograph for Professionals\|url=https:~~//www.drugs.com/monograph/adalimumab.html\|website=Drugs.com\|publisher=American Society of Health-System Pharmacists\|archive-url=https://web.archive.org/web/20201121141501/https://www.drugs.com/monograph/adalimumab.html\|archive-date=21 November 2020\|access-date=18 March 2019\|url-status=live}}<cite class="citation web cs1" data-ve-ignore="true">[https://www.drugs.com/monograph/adalimumab.html "Adalimumab Monograph for Professionals"]. ''Drugs.com''. American Society of Health-System Pharmacists. 14 May 2018. [https://web.archive.org/web/20201121141501/https://www.drugs.com/monograph/adalimumab.html Archived] from the original on 21 November 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">18 March</span> 2019</span>.</cite></ref> Kejadian efek samping lainnya yang berpotensi antara lain infeksi serius, [[kanker]], [[anafilaksis]], reaktivasi [[hepatitis B]], gagal hati, [[sklerosis multipel]], [[gagal jantung]], dan [[anemia aplastik]] . <ref name="AHFS2019"~~>{{cite~~ ~~web \|title=Adalimumab Monograph for Professionals \|url=https:~~//www.drugs.com/monograph/adalimumab.html \|website=Drugs.com \|publisher=American Society of Health-System Pharmacists \|date=14 May 2018 \|access-date=18 March 2019 \|archive-date=21 November 2020 \|archive-url=https://web.archive.org/web/20201121141501/https://www.drugs.com/monograph/adalimumab.html \|url-status=live }}</ref> Ibu [[Kehamilan\|hamil]] tidak direkomendasikan menggunakan obat ini namun, untuk ibu [[menyusui]] mungkin aman. <ref name="BNF76"~~>{{Cite~~ book\|date=2018\|title=British national formulary: BNF 76\|publisher=Pharmaceutical Press\|isbn=9780857113382\|edition=76\|pages=1074}}<cite class="citation book cs1" data-ve-ignore="true">''British national formulary: BNF 76'' (76 ed.). Pharmaceutical Press. 2018. p. 1074. [[ISBN]] [[Special:BookSources/~~9780857113382\|<bdi>9780857113382</bdi>]].</cite></ref~~> <ref>{{Cite web\|title=Adalimumab Pregnancy and Breastfeeding Warnings\|url=https://www.drugs.com/pregnancy/adalimumab.html\|website=Drugs.com\|archive-url=https://web.archive.org/web/20210417111753/https://www.drugs.com/pregnancy/adalimumab.html\|archive-date=17 April 2021\|access-date=19 March 2019\|url-status=live}}</ref> Adalimumab merupakan [[obat ~~golongan~~ antirematik pemodifikasi penyakit]] dan [[antibodi monoklonal]] yang memiliki cara kerja dengan cara menonaktifkan [[Faktor nekrosis tumor-alfa\|tumor necrosis factor-alpha]] (TNFα). <ref name="AHFS2019"~~>{{cite~~ ~~web \|title=Adalimumab Monograph for Professionals \|url=https:~~//www.drugs.com/monograph/adalimumab.html \|website=Drugs.com \|publisher=American Society of Health-System Pharmacists \|date=14 May 2018 \|access-date=18 March 2019 \|archive-date=21 November 2020 \|archive-url=https://web.archive.org/web/20201121141501/https://www.drugs.com/monograph/adalimumab.html \|url-status=live }}</ref> Pada tahun 2002 obat ini disetujui untuk digunakan dalam medis di Amerika Serikat. <ref name="FDA approval">{{Cite web\|date=7 April 2017\|title=Drug Approval Package: Humira (adalimumab)\|url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/125057_toc.cfm\|website=U.S. [[Food and Drug Administration]] (FDA)\|archive-url=https://web.archive.org/web/20200218175026/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/125057_toc.cfm\|archive-date=18 February 2020\|access-date=18 February 2020\|url-status=live}}</ref> <ref name="AHFS2019"~~>{{Cite~~ ~~web\|date=14 May 2018\|title=Adalimumab Monograph for Professionals\|url=https:~~//www.drugs.com/monograph/adalimumab.html\|website=Drugs.com\|publisher=American Society of Health-System Pharmacists\|archive-url=https://web.archive.org/web/20201121141501/https://www.drugs.com/monograph/adalimumab.html\|archive-date=21 November 2020\|access-date=18 March 2019\|url-status=live}}<cite class="citation web cs1" data-ve-ignore="true">[https://www.drugs.com/monograph/adalimumab.html "Adalimumab Monograph for Professionals"]. ''Drugs.com''. American Society of Health-System Pharmacists. 14 May 2018. [https://web.archive.org/web/20201121141501/https://www.drugs.com/monograph/adalimumab.html Archived] from the original on 21 November 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">18 March</span> 2019</span>.</cite></ref> Obat ini masuk ke dalam [[Daftar Obat Esensial Organisasi Kesehatan Dunia]] . <ref name="WHO21st">{{Cite book\|vauthors=((World Health Organization))\|year=2019\|title=World Health Organization model list of essential medicines: 21st list 2019\|location=Geneva\|publisher=World Health Organization\|hdl=10665/325771\|id=WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO\|author-link=World Health Organization\|hdl-access=free}}</ref> == Referensi == [[Kategori:Obat Esensial Organisasi Kesehatan Dunia]] [[Kategori:Obat yang dikembangkan oleh AbbVie]] [[Kategori:~~Farmasi~~Antibodi monoklonal]] [[Kategori:imunosupresan]] [[Kategori:Penghambat faktor nekrosis tumor]] [[Kategori:Obat piatu]]